MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may reverse cognitive decline in Parkinson’s disease patients who also exhibit Alzheimer’s-related amyloid pathology, a finding the company says could reshape treatment strategies across neurodegenerative diseases.
In a Phase 3 study of early Parkinson’s disease, the drug halted cognitive decline across the overall patient population, with the strongest improvements seen among those with mild dementia. Roughly one-quarter of the study participants showed amyloid co-pathology — a factor linked to more aggressive cognitive deterioration — yet their decline was reversed when treated with buntanetap.
The findings reinforce a longstanding premise at Annovis: neurodegenerative diseases seldom act alone. Instead, overlapping toxic proteins associated with both Alzheimer’s and Parkinson’s often drive cognitive and functional loss. Company scientists say buntanetap’s ability to simultaneously target multiple harmful proteins positions it as a promising candidate for complex neurological conditions.
Researchers also reported meaningful reductions in key biomarkers of neurodegeneration — including pTau217, total tau, and brain-derived tau — further indicating that the therapy may be modifying underlying disease mechanisms rather than simply alleviating symptoms.
“What we see is that Parkinson’s patients who experience cognitive decline also have Alzheimer’s pathology, and our drug helps them,” said Cheng Fang, senior vice president of research and development at Annovis Bio. “These data are the first of its kind — no one has previously looked into treatment effects in Parkinson’s patients with amyloid co-pathology.”
The company will present the full biomarker dataset at the Clinical Trials on Alzheimer’s Disease conference in San Diego from Dec. 1–4, with additional presentation details to be announced in a separate release.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.